Cochrane review of dihydroartemisinin-piperaquine for treating uncomplicated malaria

January 21, 2014

'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM.

Dihydroartemisinin-piperaquine is one of five artemisinin-based combination therapies currently recommended by the World Health Organization (WHO), and this finds that it is also one of the most studied. The team of authors from South Africa, Kenya, Geneva and Liverpool included 27 randomized studies, enrolling 16,382 adults and children, which directly compared the relative efficacy and safety of dihydroartemisinin-piperaquine and the widely used alternatives; artemether-lumefantrine, plus mefloquine, and artesunate plus amodiaquine.

"The very long duration of action of piperaquine in this combination, means that DHA-P reduces the risk of the person suffering another bout of malaria for up to nine weeks after treatment", explained David Sinclair from LSTM. "This gives it an advantage over most of the other combinations. Mefloquine has a similarly long duration of action but commonly causes such as nausea, vomiting and dizziness."

Dihydroartemisinin-piperaquine also became one of the few antimalarials to be formally registered by a stringent regulatory authority when the European Medicines Agency approved it for use in 2013. The registration process highlighted concerns that dihydroartemisinin-piperaquine caused some short term changes in electrocardiographs tracing the conduction of the heart rhythm. The review also examined this effect, and the authors report that the number of people affected by these changes is small and all resolved spontaneously without serious consequences.

Explore further: Malaria treatment could improve in children

More information: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria, Babalwa Zani, Michael Gathu, Sarah Donegan, Piero L Olliaro and David Sinclair. Published Online: 20 JAN 2014. onlinelibrary.wiley.com/doi/10.1002/14651858.CD010927/abstract

Related Stories

Malaria treatment could improve in children

December 3, 2013

An analysis of patients from across the malaria endemic world suggests that a key antimalarial treatment could be improved by better dosing in young children.

New combination malaria treatment equally effective

April 5, 2012

(HealthDay) -- Fixed-dose, combination pyronaridine-artesunate treatment is as effective as mefloquine plus artesunate in treating malaria infection, according to a study published in the April 5 issue of the New England ...

Recommended for you

Researchers discover rare flu-thwarting mutation

September 29, 2016

A rare and improbable mutation in a protein encoded by an influenza virus renders the virus defenseless against the body's immune system. This University of Rochester Medical Center discovery could provide a new strategy ...

Utah man may have contracted Zika from dying father's tears

September 29, 2016

A Utah man who mysteriously contracted Zika from his infected father may have got it by touching his dad's tears or sweat with his bare hands, according to new research unveiled Wednesday that found the unusual transmission ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.